BioAge Labs Execs to Present at Key Investor Conferences Amid Critical Data Readouts — BioAge Labs, Inc.

Event summary

BioAge Labs executives to present at ROTH Healthcare Opportunities Conference (Sept. 29) and Stifel Virtual Cardiometabolic Forum (Sept. 30).
BJ Sullivan, Dov Goldstein, and Alexis Jakubowski to participate in one-on-one meetings at both conferences.
Fireside chat with BJ Sullivan scheduled for Sept. 30 at 1 PM EDT during Stifel forum.
Phase 2 cardiovascular proof-of-concept data for BGE-102 expected in second half of 2026.
Phase 2 diabetic macular edema data for BGE-102 anticipated in second half of 2027.

The big picture

BioAge Labs is positioning itself for key investor engagement ahead of pivotal clinical data readouts. The company's focus on targeting aging biology for cardiometabolic diseases places it in a growing sector where inflammation modulation is gaining traction. The upcoming conferences provide a platform to communicate its scientific and commercial strategy as it approaches critical inflection points in its pipeline.

What we're watching

Clinical Milestones: How the upcoming Phase 2 data for BGE-102 will impact BioAge's valuation and investor sentiment.
Market Positioning: Whether BioAge can establish BGE-102 as a best-in-class NLRP3 inhibitor in the competitive cardiometabolic space.
Strategic Messaging: The effectiveness of BioAge's investor outreach during these conferences in light of critical upcoming data.